UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): February 8,
2017
Cocrystal Pharma, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-55158
|
|
20-5978559
|
|
(State
or other Jurisdiction of Incorporation)
|
|
(Commission File
Number)
|
|
(IRS
Employer Identification No.)
|
|
1860 Montreal Rd,
Tucker, GA
|
|
30084
|
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (425) 398-7178
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item
5.02
Departure
of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers; Compensatory Arrangements of
Certain Officers
On February 23 2017, Cocrystal Pharma, Inc. (the
“Company”) entered into an agreement with James J.
Martin to serve as the interim Chief Financial Officer of the
Company as an independent contractor beginning February 27, 2017.
Mr. Martin will be compensated $125 per hour up to a maximum of
$7,500 per week.
Mr. Martin, 50, has served as Chief Financial Officer of
Non-Invasive Monitoring Systems, Inc. (OTCPink:NIMU) since January
2011. Since November 2016, he has served as Chief Financial Officer
of Motus GI Holdings, Inc, a privately held medical device company.
From September 2014 to November 2016 Mr. Martin served as Chief
Financial Officer of VBI Vaccines Inc. (formerly SciVac
Therapeutics, Inc.) (NASDAQ: VBIV), a pharmaceutical development
and manufacturing company. From April 2014 to September 2015, Mr.
Martin served as Chief Financial Officer of Vapor Corp, Inc.
(NASDAQ: VPCO), a vaporizer retail and wholesale company. From
January 2011 to October 2, 2013, Mr. Martin served as Chief
Financial Officer of SafeStitch prior to its merger with
TransEnterix, Inc.
Previously, on February 8, 2017, the Company had entered an
agreement with Craig Hooson, a financial consultant with Tatum LLC,
to serve as the Company’s interim Chief Financial Officer.
The Company delayed reporting Mr. Hooson’s appointment on
Form 8-K pending its planned issuance of a press release. However,
on February 17, 2017, prior to beginning his work for the Company,
Mr. Hooson withdrew his acceptance of the Company’s
offer.
Item
9.01
Financial
Statements and Exhibits
(d)
Exhibits.
10.
1
James Martin
Consulting Agreement
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
|
Cocrystal
Pharma, Inc.
|
|
Date: February 24,
2017
|
|
|
|
By: /s/ Gary Wilcox
Name:
Gary Wilcox
Title:
Interim Chief Executive Officer
|